Further analysis also revealed that the effects of anti-VEGF therapy may be dependent on the glioblastoma genetic subtypes, e.g., IDH1 mutation status, suggesting the necessity of patient subtype stratification before clinical trials [74]. Here, VEGFA is linked to glioblastoma.